Exelixis CEO Eyes Expanded Indications For Cabozantinib
Executive Summary
In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.
You may also be interested in...
Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
The Tecentriq/Avastin Combo: Roche Details Renal Cell Cancer Benefits
Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.
Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too
Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.